Value-Based Contracting and Specialty Pharmaceuticals: ...
Value-Based Contracting and Specialty Pharmaceuticals: A Synthesis of Implications from Key Opinion Leaders (KOLs)
Drug developers no longer have FDA approval as their top concern. Now payer coverage, access and reimbursements are the primary concern. Payer resistance to pay for treatment failures is growing when individual patient specialty drug therapy costs are $200k-$2+m. Meanwhile, specialty pharmaceuticals are expected to increase to >50% of total US drug expenditure by 2022. How has value-based contracting been impacting this high stakes challenge and what is in store for the future?
Click here to access the Quality Innovation Series registration page to register or review the full course content.
Jordana Barona, MBA, MPH
Product Development Manager, NCQA
Scott J. Kornhauser
SJ Kornhauser Consulting
This live course grants 1.0 Continuing Education Unit (CEU) points for PCMH Certified Content Experts.
* Please note – You must attend the entire program to be eligible for total number of contact hours.
- 1.00 Participation
- 1.00 PCMH CCE